Introduction {#Sec1}
============

The use of cardiopulmonary bypass (CPB) is necessary for the correction of many complex cardiac defects in neonates and infants. Surgical results for most defects have improved over the last several years, but there persists significant morbidity related to the inflammatory insult of CPB. CPB in combination with anaesthesia, medication, vascular injury and surgical stress affects the extent of inflammatory response. Complement system protein may be activated through the classical, alternative and lectin pathways, leading to generation of biologically active products, such as C5a and the terminal membrane attack complex (MAC), and ultimately contributes to endothelial cell disruption during CPB. Significant differences in the complement factor levels indicate a higher grade of complement activation and simultaneous contact activation in patients during and after CPB. Thus, the main cause of systemic inflammatory reaction after CPB is the contact of the blood to non-biologic surfaces of the CPB circuit and not surgical procedures or anesthesia. To lessen the activation of the complement and contact systems during CPB, it is necessary to use inert materials in the CPB circuit. Because inhibiting drugs may lessen complement and contact system activation, they represent a further possibility for minimizing the damaging effects of CPB \[[@CR1]\].

Complement factor C1 esterase inhibitor (C1-inh) levels decrease with CPB in infants. Stiller and colleagues \[[@CR2]\] examined C1-inh levels in such patients. They found that after CPB, generalized edema, pulmonary edema, and weight gain were greater in infants with lower C1-inh levels. At 30 min post-CPB, the infants demonstrating these effects had C1-inh activity levels that were 51% of controls compared with 80% of controls in those who did not demonstrate capillary leak syndrome (CLS). This decrease was greater in infants who suffered post-CPB CLS. CLS show evidence of complement activation, decreased complement levels. We thus consecutively investigated several complement compounds before and after pediatric cardiac surgery with CPB. Based on this hypothesis, we tested whether C1-inh supplementation after CPB would ameliorate C1-inh decrease in pulmonary and cardiac dysfunction after CPB. Our prospective study was therefore designed to determine which part of the systemic inflammatory response after cardiac operations resulted from CPB in neonates and infants.

Patients and methods {#Sec2}
====================

After approval by the human ethical committee of the Gunma Children's Medical Center (GCMC) and informed consent of the parents, 40 consecutive term congenital heat disease patients aged until 1 year who underwent long CPB time (\> 3 h) at surgery were included in the prospective study between January 2012 and December 2014. Though there was no evidence, it was thought that congenital heart disease patients who underwent short CPB time did not present pulmonary edema and capillary leak syndrome. Conventional general anesthesia was conducted with diazepam, fentanyl sulfate, and vecuronium. After induction of anesthesia, nasotracheal intubation was performed in the patients not receiving ventilatory support, and central venous catheters and peripheral arterial catheter were inserted. Perioperative antibiotic prophylaxis consisted of ampicillin. The CPB circuit included a roller pump, a disposable membrane oxygenator, and an arterial filter. Cooling and rewarming were carried out with a heat exchanger. The priming solution consisted of a crystalloid solution, mannitol (3 ml/kg), and leukocyte-depleted packed red blood cells to obtain a hematocrit value of the circulating volume of about 25%. For vasodilatation in the cooling and rewarming periods, all neonates received a continuous infusion of sodium nitroprusside 2 μg/kg/min and chlorpromazine 1 mg/kg. CPB was instituted with a perfusion index of 2.7 L/(min m^2^), which was maintained throughout the cooling phase. The pump was primed with 80--100 ml of packed cells and 50 ml of lactated Ringer's solution, 1000 IU of heparin, 2.0 ml/kg of sodium bicarbonate 4.2%, and 3 ml/kg of mannitol 20% were added. CPB was instituted at a flow rate of 2.7 L/min/m^2^ after systemic anticoagulation, and administration of dexamethasone, 1 mg/kg. During CPB the pH--stat method was used, with correction of PaO~2~ to the patients' hypothermic temperature to maintain a pH value of 7.40. After deep hypothermia was reached (minimal nasopharyngeal temperature averaging 25 °C), aortic cross-clamping was done and cardioplegia was induced with a single intra-aortic injection of a 4 °C cold St. Thomas solution (30 mL/kg), and cardiac arrest was instituted for a target period of not longer than 60 min. The surgical procedure was continued under high-flow perfusion (50% of the calculated initial perfusion rate). Rewarming was achieved under full-flow conditions. The lungs of the neonates were reventilated when core temperature reached 30 °C. Neutralization of heparin was achieved with protamine sulfate in a 1:1.5 ratio. Epinephrine, dopamine, olprinone and nitroglycerin were systematically administered for weaning the patients from CPB. After coronary reperfusion and at the end of the operation, the cardiac surgeon, as explained, assessed intraoperative myocardial function here. In cases of hemodynamic instability or myocardial dysfunction at the end of the operation, sternal closure was delayed until stabilization, and sternal wounds were closed with a polytetrafluoroethylene (PTFE) membrane.

C1-inhibitor drug (\@Berinert) dosing and postoperative care {#Sec3}
------------------------------------------------------------

C1-inh drug (\@Berinert) was generously provided by CSL Behring (King of Prussia, PA). The C1-inh (20 IU/kg) was given intravenously after CPB. If necessary, fentanyl and midazolam were administered for analgesia and sedation. All patients were weaned from the ventilator as soon as possible. Dopamine and epinephrine were infused continuously as necessary to optimize mean arterial pressure, central venous pressure, pulse amplitude, capillary refill time, and diuresis. Furosemide, ethacrynic acid, and spironolactone were administered to promote diuresis.

Collection of samples {#Sec4}
---------------------

Blood samples for complement factors were obtained before and 48 h after administration of C1-inh. Arterial blood gas analysis was performed, and hemodynamic parameters were evaluated at the second day points.

Statistical analysis {#Sec5}
--------------------

Differences in the measured parameters in the two groups were assessed by the Mann--Whitney *U* test. We investigated the influence of age, weight, and sex on the determined concentrations and activities in a multiple regression analysis. Statistical significance was assumed when the *p* value was less than 0.05.

Results {#Sec6}
=======

Six patients (two that received Berinert and four that non-received Berinert) did not survive and their data were not included. These patients need the extracorporeal membrane oxygenation until 48 h after an open-heart operation in operating room and in the intensive care unit. Accordingly, obtaining the blood samples of complement factors until 48 h after administration of C1-inh was not possible. Of 34 patients included, median age was 6.5 months, median body weight was 6050 g, and 16 (47%) were female. Table [1](#Tab1){ref-type="table"} shows the mean age, body weight, diagnosis, duration of operation, duration of anesthesia, duration of CPB time, duration of aortic cross-cramp time, and nadir body temperature with C1-inhibitor non-treated group (non-INH, 26 cases) and Table [2](#Tab2){ref-type="table"} with C1-inhibitor treated group (INH, 8 cases). According to the Mann--Whitney *U* test, there were no differences between the two groups concerning demographic and intraoperative data. There were no differences between the two groups concerning demographic and intraoperative data (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Postoperative chemical data and 48 h after CPB, AST, ALT, lactate, CK-MB, WBC, CRP, duration of inotropic support, duration of mechanical ventilation and duration of ICU stay did not differ between the two groups (Table [3](#Tab3){ref-type="table"}). The results of the pre and postoperatively activated complement and contact system are summarized in Table [4](#Tab4){ref-type="table"}. Preoperatively, there were no differences in complement between two groups. Postoperatively, C1q concentration was only significant lower in patients with C1-inhibitor non-treated group than in patients with C1-inhibitor treated group. But, the consumption of C1q, C3, C4, CH~50~ and C1-inh in patients with C1-inhibitor non-treated group was observed early postoperatively. C1-inhibitor activity differed in the two groups.Table 1Clinical data and duration of cardiac operation with C1-inhibitor non-treated groupNoSexAge (m)BW (g)DiagnosisProcedureDuration of operationDuration of CPB timeDuration of ACC timeNadir BT during CPB1F0.23500TGAASO61321911230.12M0.332937TGAASO33121011927.83M0.42800TGAASO37724511829.24F0.472670TGAASO44027814127.85F23390AS, IAA, VSDNorwood6194619829.66M33500CoA, VSDCoA repairVSD closure4102129628.87M34324AS, CoA DORVNorwood44528210225.48F33170TAPVC (II)SA, VSDTAPVC repair VSD closure44527313628.89M44500AS, IAA VSDNorwood4572878725.810M46000SV, CoAArch repair, BDG56036512331.211M44054SV. CAVVRcAVV repair, BDG439304772812F44900AS, IAA VSDNorwood56937610729.713F45000DORV, LVOTOASO45130818429.114F56100cAVSDcAVSD repair3902377532.915F74760CoA, SV, s/pBTSCoA repair, BDG4262574228.116M77300TOFToF repair38125513434.417M88400SVDKS, BDG38121610530.318F87200DORV, PARastelli ope40123412831.219F86800TOF, PARastelli ope45128414131.920M97700SVDKS, TCPS3752185332.121M94500VSD,s/p CoA repairVSD closurePA plasty355190883422F107600TOFToF repair33222812434.323M118400DORVDORV repair4342671433424M118900cAVSDcAVSD repair56440123029.725M117400VSDVSD closure48428916233.726M116500cAVSDcAVSD repair34718811434.4Median4.54950436.526211629.9Table 2Clinical data and duration of cardiac operation with C1-inhibitor treated groupNoSexAge (m)BW (g)DiagnosisProcedureDuration of operationDuration of CPB timeDuration of ACC timeNadir BT during CPB1M0.073240TAPVC, CoATAPVC repairArch repair5392368325.92M63446HLHSNorwood9003975725.13F66200cAVSDcAVSD repair57220212732.94F86600TOF, PARastelli49026011431.95F116700VSD, PSVSD closurePA plasty41018510834.86M117290IAA, VSDs/p NorwoodRastelli62525514333.77F118700cAVSDcAVSD repair51526018529.18F116600cAVSDcAVSD repair57826519732.1Median9.5660041725812132.0Table 3Post-operative clinical outcome dataC1-inhibitor non-treated group (*n* = 26)C1-inhibitor treated group (*n* = 8)*P*valueAST (\< 30 IL/l) Post 0 h157.9 ± 74.2195.3 ± 87.90.51 Post 48 h52.4 ± 26.367.9 ± 27.70.43ALT  (\< 30 IL/l) Post 0 h18.9 ± 13.725.4 ± 9.50.15 Post 48 h20.4 ± 12.426.8 ± 15.00.28Lactate (0.5--1.6 mmol/l) Post 0 h1.7 ± 1.81.8 ± 1.60.63 Post 48 h1.0 ± 0.41.1 ± 0.50.39CK-MB (\< 20 U/l) Post 0 h130.9 ± 63.5155.6 ± 87.10.69 Post 48 h44.0 ± 65.822.3 ± 9.90.55WBC (\< 9000/μL) Post 0 h10,796 ± 317312,512 ± 27400.13 Post 48 h10,939 ± 299612,112 ± 25800.16CRP (\< 0.3 mg/dl) Post 0 h0.3 ± 0.30.1 ± 0.20.30 Post 48 h8.3 ± 5.58.6 ± 5.80.66Duration of inotropic support (h)204.9 ± 101.8180.8 ± 109.30.57Duration of mechanical ventilation (h)179.3 ± 121.8164.4 ± 115.00.78Duration of ICU stay (days)12.8 ± 6.012.8 ± 9.10.85Table 4Pre and postoperative complement dataC1-inhibitor non-treated group (*n* = 26)C1-inhibitor treated group (*n* = 8)*P* valueC1q (8.8--15.3 mg/dl) Pre6.14 ± 2.126.46 ± 1.220.508 Post4.77 ± 0.925.86 ± 1.13**0.045** *P* value**0.048**0.564C1 inh (70--130%) Pre93.2 ± 18.790.9 ± 22.20.964 Post71.3 ± 13.780.4 ± 18.00.115 *P* value**\< 0.001**0.3706C3 (86--160 mg/dl) Pre80.0 ± 17.179.0 ± 24.90.873 Post56.3 ± 11.561.8 ± 11.60.121 *P* value**\< 0.001**0.124C4 (17--45 mg/dl) Pre16.2 ± 6.615.8 ± 3.20.964 Post10.9 ± 4.112.3 ± 3.00.628 *P* value**0.002**0.072CH~50~ (25--50/ml) Pre43.0 ± 14.037.6 ± 21.80.873 Post31.9 ± 13.331.3 ± 21.20.792 *P* value**0.042**0.482Bold values indicate worse results than another group

Discussions {#Sec7}
===========

There are three kinds of course inclusive of classical pathway, alternative pathway and lection pathway, which activated by many factor that much protein in a complement system in sequence. To the best of our knowledge, cardiopulmonary bypass can result in a post-CPB syndrome that is characterized by increased vascular permeability, generalized edema, pulmonary dysfunction, and cardiac dysfunction \[[@CR3]--[@CR5]\]. This syndrome seems to be more intense in neonates and can result in prolonged ventilation, coagulopathy, postcardiotomy cardiac failure, and increased mortality. This is a systemic inflammatory response that appears to be fueled by activation of the complement, contact, coagulation, and fibrinolytic pathways \[[@CR6]\]. More recently, Tassani et al. have shown that prophylactic administration of C1INH before CPB is an effective therapeutic approach to reduce the inflammatory response and improve clinical parameters after cardiac surgery requiring CPB in neonates \[[@CR7]\].

Thus, although the complement system is originally a defense system for protection against foreign microorganisms, its strong activation induces excessive complement consumption and persistent inflammatory reactions. After surgery, it impairs vascular endothelial cells in the lungs and kidneys, causes swelling of parenchymal cells, and triggers an organ failure. Therefore, multiple defense systems are established by several proteins, called complement regulators, to prevent excessive and persistent complement activation and invasion of autologous cells \[[@CR8], [@CR9]\]. C1-inhibitor, called C1 inactivator, covalently binds to and inhibits the active sites (serine) of activated C1r and C1s in the C1 step of the classical pathway to suppress complement activity. In addition, it inhibits, the enzymatic activities of the coagulation, kallikrein, and plasmin systems, besides the complement system. In fact, in cases deficient in congenital complement control (e.g., Hereditary Angioedema; HAE), bradykinin, as well as C3a and C5a strongly induced by the classical pathway initiated by C1 activation, is deeply involved \[[@CR10]\].

In the present study, after the prolonged use of CPB, complement components significantly reduced by about 20--40%, as reported by the authors. In the C1-INH-treated group, it reduced by about 15%, suggesting suppressed complement reduction. Of note, there is a significant difference in the values before and after C1-INH treatment between the two groups. The lower value in the C1-INH-treated group is explained by the activation of the classical pathway through the replenishment of complements by C1-INH treatment. In the future, bradykinin and cytokine levels will be examined.

In summary, C1 INH is an important regulator of plasma protein cascade systems such as the classical pathway of complement, the intrinsic pathway of coagulation and inflammatory reactions. Thus, severe diminished C1 INH in pediatric cardiac surgery with cardiopulmonary bypass plays a vital role in activation of these systems. This study proposes the administration of C1 INH is an effective therapy to reduce the activation and improve the clinical capillary leak syndrome.

Limitations {#Sec8}
===========

Despite the strengths of our methodology and the consistency of our findings, some limitations should be delineated. First, although powered to detect a difference in postoperative CLS between those who did and did not receive C1-inh, the dosage of C1-inh was relatively small and the incidence of CLS was lower in this study. It is therefore possible that the large dosage may observe the difference in those groups in large trials. Second, anesthetic management was left to the discretion of treating anesthesiologists. This may have affected the outcome given the potential differing effects of anesthetic medications on the development of postoperative CLS. Third, the limited sample size from a single center and restrictive inclusion may place some limitations on generalizability. As this was a single-center study, the results should be replicated in a large multi-center trial.

ACC

:   Aortic cross clamp

AS

:   Aortic stenosis

ASO

:   Arterial switch operation

BDG

:   Bidirectional Glenn

BT

:   Body temperature

BTs

:   Blalock--Taussig shunt

BW

:   Body weight

CAVVR

:   Common atrioventricular valve regurgitation

cAVSD

:   Complete atrioventricular septal defect

CLS

:   Capillary leak syndrome

CoA

:   Coarctation of the aorta

CPB

:   Cardiopulmonary bypass

C1-inh

:   C1 esterase inhibitor

DKS

:   Damus--Kaye--Stanse procedure

DORV

:   Double outlet right ventricle

GCMC

:   Gunma Children's Medical Center

HAE

:   Hereditary angioedema

HLHS

:   Hypoplastic left heart syndrome

IAA

:   Interruption of the aorta

LVOTO

:   Left ventricular outlet tract obstruction

MAC

:   Membrane attack complex

PA

:   Pulmonary artery

PTFE

:   Polytetrafluoroethylene

SA

:   Single atrium

SV

:   Single ventricle

TAPVC

:   Total anomalous pulmonary vein connection

TAPS

:   Total cavo-pulmonary shunt (Kawashima procedure)

TGA

:   Transposition of the aorta

ToF

:   Tetralogy of Fallot

VSD

:   Ventricular septal defect
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